NCT00669656已完成2 期
A Phase II Trial of a Combination Herbal Therapy for Men With Biochemical Recurrence of Prostate Cancer After Initial Local Therapy
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 43
- 试验地点
- 1
- 主要终点
- The primary endpoint of this trial will be PSA response
研究概览
简要总结
This study is about Prostate Health Cocktail, a combination supplement that contains vitamin D3, vitamin E, selenium, green tea extract, saw palmetto, lycopene, and soy derivatives. This product is currently available on the market, as herb and vitamin supplements are not regulated by the FDA. Each ingredient has been studied in prostate cancer cells and/or in patients with prostate cancer. At the doses included in this supplement, no serious side effects have been reported.
The purpose of this study is to find out whether Prostate Health Cocktail can lower your PSA. Additionally, we will be looking to see whether taking this treatment causes any unexpected side effects, and whether certain blood tests can inform us about your disease status in addition to your PSA
详细描述
Objectives of this study are:
- To assess the PSA response in prostate cancer patients who have a PSA-only disease recurrence after curative local therapy, during treatment with a combination herbal supplement.
- To qualitatively and quantitatively describe the toxicity profile of this herbal supplement.
- To assess changes in PSA doubling time for subjects treated with this supplement.
- To measure tissue GRP78, serum neuroendocrine markers, and circulating tumor cells, for correlation with treatment response and prostate cancer outcomes
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Age greater than or equal to 18
- •Histologically documented adenocarcinoma of the prostate
- •Initial treatment with radical prostatectomy or external beam radiation
- •Neoadjuvant/Adjuvant Androgen Deprivation therapy allowable, provided it was for a maximum of 24 months, with the last dose of medication at least 12 months previously
- •Neoadjuvant or adjuvant chemotherapy allowable, provided it was for a maximum of 6 months, with the last dose of medication at least 12 months previously
- •Adjuvant radiation after radical prostatectomy is allowed, provided at least 6 months have elapsed between completion of radiation and enrollment in study
- •PSA recurrence, with a rising PSA, as defined by:
- •Post Radiation Therapy:
- •Absolute PSA >2.0 ng/mL
- •PSA nadir <4 ng/mL after radiation
- •Absolute rise of at least 0.5 ng/mL total
- •At least 2 increases in PSA, separated by at least 2 weeks; these can be separated by a PSA value which declines provided the second rising value is higher than the first rising value.
- •Post Prostatectomy:
- •Absolute PSA >1.0 ng/mL
- •Absolute rise of at least 1 ng/mL total from nadir
- •At least 2 increases in PSA separated by at least 2 weeks; these can be separated by a PSA value which declines provided the second rising value is higher than the first value
- •PSA Doubling Time (PSA DT) more than 3 months and less than 36 months
- •PSA DT to be calculated using the web-based calculator at http://kevin.phys.unm.edu/psa/ with the following constraints:
- •At least 3 values, but no more than 6
- •All values must be >0.2
- •Values must be separated by at least 2 months
- •No radiographically evident bony or soft tissue metastases
- •Documented discussion between subject and physician about the option to pursue hormone therapy and/or salvage local therapy rather than enroll in this study
- •Patients who received treatment with androgen deprivation for biochemical recurrence are eligible provided:
- •They did not document castration resistance (defined as 2 rising PSA values while testosteron < 50
- •They have been off androgen deprivation for at least 3 months and have recovered their testosterone (>150)
- •They have decided,in conjunction with their treating physician that they do not want to resume androgen deprivation
- •ECOG Performance Status 0-2
- •Life expectancy > 12 months
- •Adequate hepatic function (AST, ALT, bilirubin <1.5 x ULN)
- •Adequate renal function (eGFR by Cockcroft-Gault or comparable calculation >50 ml/min)
- •Willing to discontinue all nutritional supplements and 5-alpha reductase inhibitors (finasteride, dutasteride) for the duration of study treatment, unless the medication is being used to control symptoms of BPH and the patient has been taking the medication for more than 6 weeks
- •Willing to discontinue all weight control medications for the duration of study treatment
- •Signed informed consent
排除标准
- •Atypical prostate carcinoma histology (ex: small cell, adenoid cystic)
- •Evidence of bony or soft tissue metastatic disease on CT/MRI or bone scan or PET/CT
- •Other invasive malignancy within prior 3 years, except for fully treated basal cell or squamous cell carcinoma of the skin.
- •Full-dose anticoagulation therapy (warfarin or low molecular weight heparin) or antiplatelet therapy (clopidogrel or ticlopidine), with the exception of low-dose aspirin therapy (81 mg).
- •Significant cardiac disease, included but not limited to angina, myocardial infarction, cardiomyopathy, congestive heart failure, and coronary artery disease which has required bypass surgery, angioplasty or stent placement.
- •Significant uncontrolled comorbid condition which, in the opinion of the treating physician would compromise the subject's ability to comply with protocol requirements, or would pose undue risk for experiencing adverse events.
研究组 & 干预措施
Prostate Health Cocktail
Experimental
干预措施: Prostate Health Cocktail (Drug)
结局指标
主要结局
The primary endpoint of this trial will be PSA response
时间窗: PSA measurement every 4 weeks
次要结局
- Toxicity and side effects(Assessed every 4 weeks)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Vitamin D3 Supplementation in Participants Diagnosed With Early-Stage Prostate Cancer Who Decide to Undergo Active Surveillance Treatment Regimen.Prostate CancerNCT01045109Medical University of South Carolina52
已完成
2 期
Supplementation of VigantOL® Oil Versus Placebo as Add-on in Patients With Relapsing Remitting Multiple Sclerosis Receiving Rebif® TreatmentRelapsing-Remitting Multiple SclerosisNCT01285401Merck KGaA, Darmstadt, Germany260
已完成
不适用
RCT of a Polyherbal Dietary Supplement for PrediabetesPrediabetic StateNCT03388762University of Maryland, Baltimore39
招募中
3 期
Vitamin D for Prostate Endocrine TherapyStage I Prostate Cancer AJCC v8Stage II Prostate Cancer AJCC v8Stage III Prostate Cancer AJCC v8Stage IVA Prostate Cancer AJCC v8NCT05838716University of Rochester240
尚未招募
3 期
A Trial to Investigate the Efficacy and Safety of NW Low-Glu® in Patients With Type II Diabetes MellitusDiabetes Mellitus, Type 2NCT06140485Natural Wellness Egypt400